Immutep limited

Immutep are global leaders in the understanding and development of therapeutics that modulate Lymphocyte Activation Gene-3 or “LAG-3” which is a cell surface molecule which plays a vital role in regulating T cells. LAG-3 was discovered by our Chief Scientific Officer and Chief Medical Officer Dr. Frederic Triebel, putting Immutep at the forefront of immunotherapy drugs for cancer and autoimmune diseases.
The companies objective is to harness and strengthen the power of the body’s own immune systems through therapeutic intervention for the benefit of patients’ health. This is how immunotherapy fights cancer and autoimmune disease.

Exchange Code

ASX code IMM

Sector

Pharmaceuticals- Biotechnology & Life Sciences

CCR Report

Company news

We help investors gain insights into your company through high quality research reports.

We provide a full suite of corporate access services.

 
 
 
Corporate Connect Research

79 Kent Street
Millers Point
Sydney NSW 2000

Email us

Contact us

6 + 12 =